Nitinan Chimparlee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nitinan Chimparlee has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Alisara Anannab
Department of Cardiovascular and Intervention, Central Chest Institute of Thailand, Nonthaburi, Thailand (A.A.).
2 shared publications - Connie R. Bezzina
Amsterdam Cardiovascular Sciences, Cardiomyopathy and Arrhythmia, Amsterdam, Netherlands
2 shared publications - John Mauleekoonphairoj
Centre of Excellence in Arrhythmia Research, Department of Medicine, Faculty of Medicine, Chulalongkorn University
2 shared publications - Koonlawee Nademanee
Pacific Rim Electrophysiology Research Institute at Bumrungrad Hospital, Bangkok, Thailand
2 shared publications - Montawatt Amnueypol
Departments of Medicine, Faculty of Medicine at Ramathibodi Hospital (M.A., T. Ngarmukos), Mahidol University, Bangkok, Thailand
2 shared publications - Rungroj Krittayaphong
Division of Cardiology, Department of Medicine, Faculty of Medicine Siriraj hospital Mahidol University Bangkok Thailand
2 shared publications
Latest Publications
- Open Access
- 7 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (1) , 31-44
A Rare Noncoding Enhancer Variant in SCN5A Contributes to the High Prevalence of Brugada Syndrome in Thailand
BACKGROUND: Brugada syndrome (BrS) is a cardiac arrhythmia disorder that causes sudden death in young adults. Rare genetic variants in the SCN5A gene encoding the Na v 1.5 sodium channel and common noncoding variants at this locus are robustly associated with the condition. BrS is particularly prevalent in Southeast Asia but the underlying ancestry-specific factors remain largely unknown. METHODS: Genome sequencing of BrS probands and population-matched controls from Thailand was performed to identify rare noncoding variants at the SCN5A-SCN10A locus that were enriched in patients with BrS. A likely causal variant was prioritized by computational methods and introduced into human induced pluripotent stem cell (hiPSC) lines using CRISPR-Cas9. The effect of the variant on SCN5A expression and Na v 1.5 sodium channel current was then assessed in hiPSC-derived cardiomyocytes (hiPSC-CMs). RESULTS: A rare noncoding variant in an SCN5A intronic enhancer region was highly enriched in patients with BrS (detected in 3.9% of cases with a case-control odds ratio of 45.2). The variant affects a nucleotide conserved across all mammalian species and predicted to disrupt a Mef2 transcription factor binding site. Heterozygous introduction of the enhancer variant in hiPSC-CMs caused significantly reduced SCN5A expression from the variant-containing allele and a 30% reduction in Na v 1.5-mediated sodium current density compared with isogenic controls, confirming its pathogenicity. Patients with the variant had severe phenotypes, with 89% experiencing cardiac arrest. CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the SCN5A locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.
- 7 January 2025
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (1) , 31-44
Open AccessA Rare Noncoding Enhancer Variant in SCN5A Contributes to the High Prevalence of Brugada Syndrome in Thailand
BACKGROUND: Brugada syndrome (BrS) is a cardiac arrhythmia disorder that causes sudden death in young adults. Rare genetic variants in the SCN5A gene encoding the Na v 1.5 sodium channel and common noncoding variants at this locus are robustly associated with the condition. BrS is particularly prevalent in Southeast Asia but the underlying ancestry-specific factors remain largely unknown. METHODS: Genome sequencing of BrS probands and population-matched controls from Thailand was performed to identify rare noncoding variants at the SCN5A-SCN10A locus that were enriched in patients with BrS. A likely causal variant was prioritized by computational methods and introduced into human induced pluripotent stem cell (hiPSC) lines using CRISPR-Cas9. The effect of the variant on SCN5A expression and Na v 1.5 sodium channel current was then assessed in hiPSC-derived cardiomyocytes (hiPSC-CMs). RESULTS: A rare noncoding variant in an SCN5A intronic enhancer region was highly enriched in patients with BrS (detected in 3.9% of cases with a case-control odds ratio of 45.2). The variant affects a nucleotide conserved across all mammalian species and predicted to disrupt a Mef2 transcription factor binding site. Heterozygous introduction of the enhancer variant in hiPSC-CMs caused significantly reduced SCN5A expression from the variant-containing allele and a 30% reduction in Na v 1.5-mediated sodium current density compared with isogenic controls, confirming its pathogenicity. Patients with the variant had severe phenotypes, with 89% experiencing cardiac arrest. CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the SCN5A locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.
- 1 June 2021
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 14 (3) , 383-386
Clinical Characteristics of SCN5A p.R965C Carriers: A Common Founder Variant Predisposing to Brugada Syndrome in Thailand
- 1 June 2021
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 14 (3) , 383-386
Clinical Characteristics of SCN5A p.R965C Carriers: A Common Founder Variant Predisposing to Brugada Syndrome in Thailand